Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Stem cell therapy for ischemic stroke: neuroimaging approaches and evidence from a systematic review

Jiang B., Zhao M., Tong E., Liu Y., Fettahoglu A., Weng WK.

Meta-analysis on Stroke Research, published in Front Neurol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Front Neurol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41743047
PMCID
PMC12931286
DOI
10.3389/fneur.2026.1718086

Abstract (original English)

Purpose Cell-based therapy is a promising approach for ischemic stroke treatment. This systematic review and meta-analysis aimed to consolidate clinical evidence on the use of neuroimaging to evaluate stem cell therapy across all stages of stroke recovery. Methods A systematic search was conducted in 5 databases in July 2025. They were included if neuroimaging analysis, regardless of cell source, route administration or dosage were reported. The level of evidence and risk of bias were assessed using the ROB-2 or ROBINS-I tool. Imaging data from all included articles were extracted, and randomized-effect meta-analyses were performed when two or more outcomes were available for any reported imaging parameter. Results Thirty articles were included in the systematic review, of which four were eligible for meta-analysis. Meta-analysis of subacute stroke patients revealed no significant differences in infarct volume reduction at 3 months (SMD = -0.50; 95% CI: -1.15 to 0.51; p = 0.13; I 2 = 63%) or 1 year (SMD = -1.02; 95% CI: -3.63 to 1.60; p = 0.45; I 2 = 92%) between treatment and control group. Chronic stroke patients exhibited less overall volume loss. There was a trend toward improved white matter recovery and motor cortex activity, reflected in increased DTI and fMRI parameters. SPIO-labeled autologous stem cells recently proved safe in patients, with T2* imaging showing engraf

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research